The putative role of oxidative stress and inflammation in the pathophysiology of sleep dysfunction across neuropsychiatric disorders: Focus on chronic fatigue syndrome, bipolar disorder and multiple sclerosis. — CFSMEATLAS
The putative role of oxidative stress and inflammation in the pathophysiology of sleep dysfunction across neuropsychiatric disorders: Focus on chronic fatigue syndrome, bipolar disorder and multiple sclerosis.
Morris, Gerwyn, Stubbs, Brendon, Köhler, Cristiano A et al. · Sleep medicine reviews · 2018 · DOI
Quick Summary
This review explores why people with ME/CFS, bipolar disorder, and multiple sclerosis often have severe sleep problems. The authors suggest that inflammation and stress in the body's cells may damage the brain's ability to control sleep and daily rhythms. They propose that when the immune system stays activated, it can trigger harmful processes that disrupt sleep, which then makes inflammation worse—creating a harmful cycle.
Why It Matters
Understanding the shared biological mechanisms driving sleep dysfunction in ME/CFS could identify new therapeutic targets and explain why sleep disruption is so debilitating in this disease. This framework suggests that anti-inflammatory and antioxidant interventions might help restore sleep quality, potentially improving overall ME/CFS outcomes.
Observed Findings
Sleep and circadian abnormalities are prevalent across ME/CFS, bipolar disorder, and multiple sclerosis.
Systemic inflammation can activate glial cells (microglia and astrocytes) in brain regions controlling sleep regulation.
Activated glial cells release pro-inflammatory cytokines and nitric oxide that may disrupt circadian gene expression.
Sleep disruption may amplify peripheral immune activation and inflammation, creating a vicious cycle.
Melatonin and molecular hydrogen are proposed as potential therapeutic targets for immune and oxidative pathways.
Inferred Conclusions
Reciprocal interactions between immune activation, oxidative stress, and mitochondrial dysfunction may be a common pathophysiological mechanism driving sleep abnormalities across neuroprogressive neuro-immune disorders.
Therapeutic approaches targeting immune and oxidative/nitrosative stress pathways may alleviate sleep and circadian dysfunction in ME/CFS and related conditions.
Breaking the cycle of sleep disruption and immune activation represents a key therapeutic opportunity in these disorders.
Remaining Questions
Do ME/CFS patients show the proposed markers of glial activation and pro-inflammatory cytokine elevation in brain regions controlling sleep?
What This Study Does Not Prove
This review does not provide direct empirical evidence that these proposed mechanisms actually occur in ME/CFS patients—it is a theoretical framework synthesizing existing literature. It does not establish causation, only proposes plausible biological pathways, and does not test whether treating inflammation and oxidative stress would actually restore sleep in ME/CFS.
Would immune-modulating or antioxidant treatments actually restore sleep quality and circadian function in ME/CFS patients?
Which of the proposed mechanisms (oxidative stress, mitochondrial dysfunction, or immune activation) is primary versus secondary in driving sleep disruption?
Are the pathways linking sleep dysfunction to neuroinflammation identical across ME/CFS, bipolar disorder, and multiple sclerosis, or are there disease-specific variations?